Sedana Medical reports NDA submission and improved EBITDA
Net sales were flat but EBITDA improved from -8% to -4%, and cash flow from operations improved.
See the latest news and media coverage for Sedana. We track all announcements, press releases, and industry mentions in real time, all in one place.
Medtech and pharmaceutical company focused on inhaled sedation
sedanamedical.comLast updated
In short: Sedana Medical submitted its New Drug Application to the FDA for inhaled sedation in the ICU and reported improved EBITDA performance.
Net sales were flat but EBITDA improved from -8% to -4%, and cash flow from operations improved.
CEO Johannes Doll, CFO Mikael Haag, and CMO Peter Sackey will present on July 17, 2026, and answer questions.
It concerns isoflurane delivered via the Sedaconda ACD for ICU inhaled sedation. FDA filing review and acceptance decision are expected in about two months.
No dividend was paid, and a performance-based incentive program for employees was approved.
Sedana Medical, active in inhalation sedation, reports an operating result of minus 9.4 million kronor for the second quarter of 2026 (minus 9.5).
Sedana Medical AB (OSTO:SEDANA) advances towards US market entry amid mixed sales performance and financial adjustments.
Sedana Medical AB (publ) today announces that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the...
Sedana Medical AB is a medical technology company, which engages in the development, manufacture, and sale of medical devices and drug development for future projects...
Track Sedana and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.